135ACTIVITIES
1ORGS REPRESENTED
45BILLS
Organizations represented
1Orgs whose LD-2 filings list Elisabeth as an active lobbyist, sorted by activity volume.
Bills they file on
45H.R. 126249 mentions
S. 52746 mentions
S. 109745 mentions
S. 109645 mentions
S. 93245 mentions
S. 4343 mentions
H.R. 648543 mentions
S. 227643 mentions
H.R. 326942 mentions
H.R. 167237 mentions
S. 86432 mentions
S. 52631 mentions
S. 109531 mentions
S. 104130 mentions
H.R. 616630 mentions
+ 30 more bills referenced in their activities
Topics in Filings
455Policy topics Elisabeth files on across all their LD-2 activities.
Medical Countermeasure Priority Review Voucher Reauthorization×146
CMMI: GLOBE and GUARD Models×112
Interagency Patent Coordination and Improvement Act×89
Preserve Access to Affordable Generics and Biosimilars Act×89
Prescription Pricing for the People Act×87
National Coverage Determination×87
International Pricing Policies×84
R&D Funding for Medical Countermeasures×79
Lowering Drug Costs for American Families Act×77
Pharmacy Benefit Manager Transparency Act×72
CMMI Authority×72
Antimicrobial Resistance×71
Show all 455 topics (+443 more) ▾
Most Favored Nation Drug Pricing Proposals×71
Stop STALLING Act×70
FY 2026 Appropriations for Specific Issues×63
Development and Procurement×57
Big Savings Act×57
Funding for Strategic National Stockpile×56
Maintaining Investments and New Innovation×56
340B Rebate Rule×56
Pandemic Preparedness×55
Development and Procurement Issues×54
Biodefense/Biomedical/Emergency Preparedness Research×53
Drug Supply Chain Management×52
Supply Chain Issues×52
FY 2026 Appropriations for Agencies×52
Centers for Disease Control and Prevention×52
Health Resources and Services Administration×52
Clinical Trial Data in China×51
HHS Office of Infectious Disease and HIV/AIDS Policy×51
Drug Pricing×50
Vaccines and Infectious Diseases×50
MCM PRV Reauthorization×43
Data Privacy Working Group Draft×42
Administration for Strategic Preparedness and Response×42
Biomedical Advanced Research and Development Authority×42
Pediatric Priority Review Voucher×42
Restrictions on Intellectual Property Rights×41
FY 2025 Appropriations×40
Vaccine Injury Compensation Program×40
Risky Research Review Act×37
Quality & Distribution×36
Advanced Manufacturing×36
Drug Shortages×36
Supply Chain Integrity and Traceability×36
Patient Cost-Sharing and Implementation×36
Alternative Payment Arrangements for Gene Therapies×36
Drug Benefit Design×36
National Defense Authorization Act×36
Adult Immunization×36
Vaccine Safety net and Vaccine Infrastructure×36
Value of Vaccines and Vaccine Confidence×36
Affordable Prescriptions for Patients Act×35
Pricing and Rebates×35
MCM Manufacturing & Capacity×35
Orphan Drug Tax Credit×35
Average Manufacturer Price Calculations×34
Support of Patient Premiums and Cost-Sharing Obligations×34
Let Injured Americans Be Legally Empowered×34
Vaccine Injury Compensation Modernization×34
Alternative Funding Programs×34
Biosimilar Red Tape Elimination Act×34
SAFE STEP Act×34
Vaccine Access Improvement Act×33
Funding for Women's Health Research×33
Medicare Drug Price Negotiation Act×33
Modernizing and Ensuring PBM Accountability×33
Value-based Contracting and Communications×32
Medicaid VBPs for Patients×32
Increasing Transparency in Generic Drug Application×31
FY 2026 Appropriations×30
Pandemic Preparedness -R&D Funding for Medical Countermeasures×30
Non-Opioid Analgesics Orphan Drug Issues×29
Biosecurity Modernization×29
Food & Drug Administration×28
National Defense Authorization Act 2027×28
Biosimilars Competition×28
CMMI×28
Pediatric Priority Review Voucher Pandemic Preparedness×28
Bio COMPETES×24
Value-Based Purchasing×24
BIOSECURE Act×23
Executive Order on Access to Affordable Life-Saving Medications×22
Strengthening Innovation in Medicare and Medicaid Act×22
Biosimilar Copay×21
Interchangeability and Pharmacy Substitution×21
Promising Pathway Act×21
Medicare Part B Physician-Administered Products×21
Maternal Immunization×21
Program Implementation & Oversight×21
Mandating Exclusive Review of Individual Treatments×21
China Biotechnology Regulations×20
Advanced Research Projects Agency for Health×20
CICP×20
PBM Reform×20
Coverage of Accelerated Approval Products×20
Patient Cost-Sharing and Smoothing×20
American Innovation and Jobs Act×20
PROTECT 340B Act×20
Prescription Drug User Fee Act×20
House GOP RFI on Supply Chain×19
Medication Affordability and Patient Integrity Act×19
TRIPS Waiver×19
Accelerated Approval Artificial Intelligence×19
COVID-19 Pricing Related Provisions×19
Countermeasures Injury Compensation Program×19
Vaccine Safety and Quality×19
VICP Loopholes×19
SUSTAIN 340B Act×19
Access to Innovative Treatments Act×19
American Privacy Rights Act×18
MCM PRV Program Reauthorization×18
WHO Pandemic Preparedness Accord Biosimilars×18
Reimbursement Cell & Gene Therapy×18
Encouraging Innovation Benefit Design to Lower Costs for Seniors Act×18
Vaccine and Antimicrobial Resistance Product Development and Incentives×18
Medicaid Drug Rebate Program×18
Countermeasure Injury Compensation Fund Amendment Act×18
CFIUS and Foreign Investment Drug Pricing×18
Pandemic Flu×18
One Big Beautiful Bill Act×18
Foreign Drug Data Protection Laws×18
Genetic Resources, and Associated Traditional Knowledge×17
State Strategic Stockpile Act×17
Expensing of R&D Expenditures×17
Biosimilars Red Tape Elimination Act×17
Influenza Planning & Response×17
Project Bioshield×17
FDA Hiring Flexibility×17
DRUG Act×17
FDA Modernization×17
Act 3.0 Medicaid×17
Innovation in Pediatric Drugs Act×17
Retaining Access and Restoring Exclusivity×17
Step Therapy×17
MCM R&D Incentives×17
Vaccine Quality Measure×17
Vaccine Safety×17
Section 232×17
Pharmacy Benefit Managers Artificial Intelligence×16
Bayh-Dole Act×16
Drug Patenting×16
Section 101 Modernization×16
Treaty on Intellectual Property×16
Diversity & Inclusion×16
Compounded Medicines×16
ORPHAN Cures Act×16
Decentralized Clinical Trials Drug Evaluation and Review×16
Precision Medicine Initiative Reimbursement and Coverage of Innovative Products×16
Disease X Act×16
Gain of function×16
SAFE Risky Research Act×16
Reference Pricing in Drug Reimbursement×16
Generic Drug Entry×16
Generic Drug Application Review Reforms×16
Incentives for Generic Entry Issues×16
Funding for Medical Countermeasures×16
Accelerated Approval Antimicrobial Resistance Artificial Intelligence×16
White House National Biodefense Strategy×15
Coverage and Reimbursement×15
Tariffs Foreign Agricultural Biotechnology Laws and Regulations×15
World Intellectual Property Office×15
Patent Tax/fees×15
Section 317 Immunization Program×15
Vaccine Injury Compensation Program 340B Drug Discount Program×15
Compounding Pharmacies×15
Contract Manufacturing Ecosystem in the United States×15
Access to Innovative Treatments×15
PASTEUR ACT×15
WHO Pandemic Preparedness Accord Pandemic Preparedness×15
VICP/CICP Antimicrobial Resistance Biodefense Research×15
Vaccines and Infectious Diseases 340B Drug Discount Program×15
Most Favored Nation in Medicaid×15
NSCEB Recommendations Opioid Crisis×15
VICP/CICP Capital Formation Incentives×15
Cameron's Law Pandemic Preparedness Research & Development Tax Credit Reforms×15
Compulsory Licensing×14
28 U.S.C. 1498×14
Patent and copyright cases Data Privacy×14
Patent Reform×14
PTAB Reform×14
Patenting of Biological Inventions×14
Centers for Medicare and Medicaid×14
National Institutes of Health×14
Purple Book Draft×14
Consumer Data Privacy and Security Act×14
Diagnostics and Personalized Medicine Regulation and Oversight×14
PDUFA VII Implementation×14
PDUFA VIII Negotiations Drug Importation Drug Manufacturing×14
NSC/OSTP priorities×14
Nucleic acid synthesis security and biotechnology governance×14
Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products×14
VICP/CICP Biodefense Research×14
Funding for Section 317×14
CDC Reform×14
FDA Hiring Staffing Drug Importation Drug Manufacturing×14
Tariffs Foreign Drug Data Protection Laws Medicaid×14
Incentives for Domestics Manufacturing Orphan Drug Issues×14
R&D Payroll Credit Vaccines and Infectious Disease×14
China Synthetic Biotech×14
US-China IP Provisions United Nations World Trade Organization×14
Monoclonal Antibody Coverage and Utilization×13
Climate Issues & impact on the agriculture and food sectors×11
SUPPORT Act×8
WHO Pandemic Preparedness Accord×8
FDA Approvals×7
Guidance, & Regulations×7
Gene Editing×7
MCM PRV Program×7
Farm Bill Reauthorization×6
Rural Development×6
Food and Drug Administration, and Related Agencies Appropriations Act×6
Incentives for Sustainable Aviation Fuels×6
Tropical Disease Priority Review Voucher×6
Safe, and Secure American Bioeconomy×6
Give Kids a Chance Act×6
Pediatric Priority Review Voucher Program×6
Temporarily Refundable R&D Credit×6
HELP Copays Act×6
HHS Reorganization×6
American Innovation and R&D Competitiveness Act×6
Most Favored Nation×6
Prescription Drug Price Relief Act×6
ASPR×6
Patent Thickets×5
Non-Opioid Analgesics×5
Administration Rebate Rule×5
Protected Classes×5
Helping Startups Continue to Grow Act×5
Small Entity Update Act×5
National Institute of Health×5
BARDA×5
Efficient Science-Based Review of Biotech Products×4
International Consistency of Regulations×4
Genetically Engineered×4
Biomass Crop Assistance, and Biorefineries×4
FY 2026 Appropriations Funding for Antimicrobial Resistance×4
Bill to address patent thickets×4
Prohibiting Adversarial Patents Act×4
Protecting Americans Data from Foreign Adversaries Act×4
Sustainable Aviation Fuels Tax Credit×4
Agricultural Biorefinery Innovation and Opportunity×4
Decentralized Clinical Trials×4
FDA Hiring Flexibility Drug Importation Drug Manufacturing×4
VICP×4
Lower Costs×4
Executive Order on Achieving Efficiency Through State and Local Preparedness×4
340B Accountability Act×4
American Innovation Act×4
Expanding Access to Capital Act×4
Fair Prescription Drug Prices for Americans Act×4
Creating Hope Reauthorization×4
Emerging New Threats and×4
Orphan Drug Issues×4
Finding Orphan-Disease Remedies with Antifungal Research and Development×4
National Defense Authorization Act 2026×4
Farm Bill×3
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance×3
Reasonable Pricing Clauses in BARDA Contracts×3
House GOP RFI on Data Privacy×3
COVID-19 Lessons Learned×3
MCM PRV×3
Coverage and Reimbursement Orphan Drug Issues×3
Orphan Drug Tax Credit Pandemic Preparedness×3
Medical Countermeasures PRV Reauthorization×3
BSUFA Negotiations×3
Compounded Medicines Drug Patenting×3
Accredited Investor Definition Review Act×3
Equal Opportunity for All Investors Act×3
Global Fairness in Drug Pricing Act×3
PPRV×3
Medicare Negotiation and Competitive Licensing Act×3
ASPR FY 2026 Appropriations for Specific Issues×3
China Synthetic Biotech Tariffs Trade Relations×3
Farm to Fly Act×2
Food & Ag National Security×2
EPA proposed revisions to regulations×2
USMCA Review×2
Office of Biopesticides and Pollution Prevention Division×2
Biotechnology and Agriculture Trade Program×2
Farm Bill Programs Energy Title IX×2
NextGen Aircraft Technology×2
Fuels & Metrics×2
Reasonable Pricing Clause Compulsory Licensing Data Privacy×2
FTC Orange Book Delisting Initiative×2
PTO Proposed Rules on Terminal Disclaimer Practice×2
China Patent Reform×2
Patent Eligibility Restoration Act×2
WHO Pandemic Preparedness Accord World Intellectual Property Office×2
Biofuels and SAF×2
IRA Tax Credits×2
Biomass Programs×2
340B Drug Discount Program×2
Biosecurity Infrastructure for Operational×2
NDAA×2
MINI Act×2
Climate Change×2
Medicaid Drug Rebate Program Rule×2
More Cures Act×2
Biodefense Research×2
Funding for Biodefense/Biomedical/Emergency Preparedness Research×2
Putting Investors First Act×2
Fair Investment Opportunities for Professional Experts Act×2
Infectious Disease Therapies Research and Innovation Act×2
Net Operating Loss Advance Refunds×2
Accredited Investor Definition×2
Amended Definition of Smaller Reporting Company×2
EU Ag-Biotech Policies×2
International Consistency of Regulation for Gene Edited Products×2
Korea Biotechnology Regulations×2
B5 Coalition on Supply Chain Resiliency×2
Cell & Gene Therapy×2
Most Favored Nation Foreign Drug Data Protection Laws×2
Project Bio Shield×2
Vaccine Access & Compensation×2
Improving Data Accessibility Through Advancements×2
Drug Evaluation and Review×2
Drug Importation Drug Manufacturing×2
Stronger Patents Act×2
Protecting Patient Access to Cancer and Therapies×2
More Transparency Act×2
VICP CICP×2
Family Vaccine Protection Act×2
Capital Formation Incentives×2
US China IP Provisions×2
National Institutes of Health FY 2026 Appropriations for Specific Issues×2
Avian Flu×1
General Climate Change×1
Mexico Decree Banning Genetically Modified Corn Funding for the USDA×1
FY 2026 Appropriations Genetically Engineered×1
EPA Regulatory Approach to Gene Editing×1
FDA Proposed guidance on Gene Editing×1
USDA Regulatory Approach to Gene Editing Interagency Coordination×1
DOE and USDA Interagency Research Act×1
Regulatory Treatment of Gene Edited Products×1
Regulatory Treatment of Biostimulants United States-Mexico-Canada Agreement×1
Avian Flu Farm Bill×1
Funding for Antimicrobial Resistance×1
FY 2026 Appropriations Pandemic Preparedness×1
Bioenergy Technology Office×1
Environmental Energy R&D×1
Patentability of AI-Aided inventions Bayh-Dole Act/Tech Transfer×1
Invent Here×1
Make Here Act×1
March-In Rights×1
Inventor Diversity for Economic Advancement×1
Title 35 to Address Infringements of Patents Claiming Biological Products×1
Protecting Consumer Access to Generic Drugs Act×1
Orange Book Listing×1
Patent Litigation Reform×1
USPTO Request for Comments: Experimental Use Defense 89 Fed×1
Reg 53963 Patenting of Biological Inventions×1
RESTORE Patent Rights Act×1
World Health Organization×1
Fighting Climate Change through Biotechnology Innovation Funding for Biofuels×1
Mitigating Climate Change through Biotechnology Innovation Funding for Biofuels×1
Program & Oversight×1
American Pandemic Preparedness Plan×1
FY 2026 Appropriations Data Privacy×1
Clinical Trial Diversity Drug Evaluation and Review×1
CICP Funding for FDA×1
User Fees Funding for Health Resources and Services Administration×1
Funding for Womens Health Research International Reference Pricing Medicaid×1
Womens Health Research Pandemic Preparedness×1
General Cell & Gene Therapy×1
FY 2026 Appropriations Clinical Trial Data in China Data Privacy×1
General Diversity & Inclusion×1
Clinical Trial Diversity×1
General Drug Evaluation and Review×1
FY2025 Appropriations×1
PBN Reform×1
International Reference Pricing Foreign Drug Data Protection Laws×1
Regulatory Harmonization Funding for Antimicrobial Resistance×1
FY 2026 Appropriations International Reference Pricing Issues×1
Innovation and Pediatric Drugs Act×1
Banking Policy×1
Impacting Emerging Companies×1
Regulatory Burden Capital Formation Incentives×1
JOBS Act 4.0×1
Market Liquidity Proposals×1
Public Float Threshold Update×1
SEC Small Business Forum×1
Small Business Capital Formation Enhancement Act×1
Mergers and Acquisitions Reform×1
Accredited Investor Certification Sarbanes Oxley Section 404×1
Small Issuer Exemption Small Business Innovation Research×1
Adjusting the well-known seasoned issues×1
Definition to allow for a larger financing round using×1
General Pandemic Preparedness Renewable Chemicals/Bio-based Products×1
Tax Relief for American Families and Workers Act×1
R&D Payroll Credit Vaccine Injury Compensation Program×1
Medical Supply Chain Resiliency Act×1
Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement×1
Ag-Biotech Provisions×1
IP Provisions World Health Organization×1
Patent Thickets Drug Pricing×1
Regulatory Harmonization Medicaid×1
Department of Energy×1
Department of Transportation×1
USDA FY 2026 Appropriations for Specific Issues×1
Environment and Energy R&D×1
Renewable Materials/BIO-based Products×1
Efforts to expand the Bio Economy & Bio Manufacturing×1
BARDA FY 2026 Appropriations for Specific Issues×1
Section 317 Immunization Program 340B Drug Discount Program×1
Accelerated Approval Access to non-human Primates×1
Climate Change Data Privacy×1
PDUFA×1
FDA Reform×1
Compounding & Counterfeit Medicines Drug Patenting×1
Rare Disease Pilot Program Pandemic Preparedness×1
End Price Gauging for Medications Act×1
SMART Prices Act×1
HHS Reorganization Pandemic Preparedness×1
Public Float Threshold Update Small Business Innovation Research×1
VICP Biofuels and SAF×1
Carbo Capture Utilization Parity Capital Formation Incentives×1
R&D Payroll Credit×1
Net Operating Loss×1
Vaccines and Infectious Disease×1
Counterfeit Drug Monitoring Drug Pricing×1
United Nations×1
US-China Ag-Biotech Provisions×1
World Trade Organization×1
Food and Ag Organization×1
National Institute of Health FY 2026 Appropriations for Specific Issues×1
Reimbursement Cell & Gene Therapy Data Privacy×1
Clinical Trial Modernization×1
Drug Rebate Program Rule×1
HHS Reorganization CDC Reform×1
Prescription Drug Pricing for the People Act×1
Capital Market Enhancements Small Business Innovation Research×1
Most Favored Nation Foreign Agricultural Biotechnology Laws and Regulations×1
ETHIC Act×1
Dept of Commerce Patent Valuation Fee Proposal×1
Intellectual Property Enforcement×1
340B ACCESS Act×1
Synthetic Nucleic Acid Synthesis Screening×1
PDUFA VIII Negotiations×1
Drug Manufacturing×1
Biologics Competition Act×1
Enhanced Access to Affordable Medicines Act×1
Most Favored Nation Pricing Opioid Crisis×1
Reimbursement and Coverage of Innovative Products×1
Administrative Rebate Rule×1
MCM PRV Program CDC Reform×1
340B Rebate Pilot Program×1
FDA Hiring Flexibility Drug Manufacturing×1
Most Favored Nation Pricing×1
Vaccine Access×1
Vaccines for Children Program×1
CMMI Models×1
Intellectual Property International Enforcement×1
Bilateral Trade Negotiations×1
Word Health Organization×1
Issue mix
LDA general-issue codes weighted by activity count.
Health Issues18
Homeland Security18
Medical/Disease Research/Clinical Labs18
Medicare/Medicaid18
Trade (domestic/foreign)18
Taxation/Internal Revenue Code17
Copyright/Patent/Trademark16
Budget/Appropriations3
Small Business3
Food Industry (safety, labeling, etc.)2